Pulmonary Embolism
New dyspnea, pleuritic pain, hypoxemia, tachycardia, syncope or unexplained deterioration after pelvic surgery warrants assessment for PE alongside bleeding, pneumonia, atelectasis, myocardial disease and sepsis. Neither a normal oxygen saturation nor an alternative plausible postoperative diagnosis excludes PE. The immediate priorities are recognition of shock, objective diagnosis when feasible, and a treatment plan that accounts for the operative bleeding site.[1]
See also: Antithrombotic Therapy for prevention/interruption/neuraxial timing, and Anticoagulation Reversal for major bleeding. Prophylactic doses do not treat an established PE.
Diagnostic Approach
Establish Probability Before Ordering D-Dimer
Use a validated pathway based on clinical probability, assessed by an appropriate score or experienced clinical judgment. Wells and revised Geneva are alternatives; scores do not universally outperform gestalt. In a patient with high probability or circulatory deterioration, do not delay imaging or emergency assessment to obtain a D-dimer.[1][2]
PERC is an option only when the initial probability is low and all eight criteria are negative: age under 50, pulse under 100, oxygen saturation at least 95%, no unilateral leg swelling, hemoptysis, prior VTE, estrogen use, or qualifying recent surgery/trauma. The latter criterion concerns surgery/trauma requiring hospitalization within four weeks. Many postoperative patients therefore cannot be ruled out with PERC; it is not a substitute for evaluating an acutely unwell inpatient.[2]
D-dimer is useful for exclusion within validated low/intermediate-probability pathways, not for confirming PE. A positive result is common after surgery, with cancer and during hospitalization. Match the cutoff to the assay and units; the standard 500 ng/mL FEU cutoff is not interchangeable with a DDU value. Age-adjustment uses age × 10 ng/mL FEU above age 50. YEARS instead adjusts the threshold to its own three clinical items; do not mix algorithms.[2][3][4]
Postoperative elevation reduces efficiency, but there is no universal rule that a negative D-dimer is invalid for exactly two weeks. ADJUST-PE included some patients with recent surgery, although it studied emergency-department outpatients, not a dedicated immediate-postoperative ward population. Choose a validated pathway for the actual setting; high probability proceeds to imaging.[3]
Imaging
CT pulmonary angiography is the usual definitive test. V/Q imaging is an alternative when contrast or other patient factors favor it and a diagnostic study is obtainable. Proximal venous ultrasound may establish VTE when chest imaging is impractical; an isolated distal calf finding requires its own interpretation. Bedside echocardiography can identify RV failure and competing causes in an unstable patient but a normal study does not exclude PE.[1][2]
Severity and Disposition
Clot location or a “saddle” appearance alone does not determine treatment. Assess blood pressure and perfusion, oxygen/support requirements, RV findings, biomarkers, comorbidity and trajectory. Normotension can coexist with shock.[2]
The 2026 AHA/ACC guideline introduces categories A–E:[2]
| Category | Clinical distinction |
|---|---|
| A | Incidentally detected, asymptomatic PE |
| B | Symptomatic PE with low clinical severity |
| C | Elevated clinical severity; subdivisions incorporate RV dysfunction and biomarkers |
| D | Incipient cardiopulmonary failure, including transient hypotension or normotensive shock |
| E | Cardiopulmonary failure with persistent/recurrent hypotension, refractory shock or arrest |
A respiratory modifier identifies additional respiratory compromise. These categories support reassessment rather than replacing clinical judgment. In particular, SBP ≥90 mmHg does not automatically mean a stable, low-risk patient.
A validated tool such as Hestia or PESI/sPESI, together with clinical assessment, can support outpatient treatment. Also establish bleeding risk, oral medication access, home support and reliable follow-up. A low score alone does not override an active surgical complication; a positive sPESI is not a complete disposition decision.[2]
Anticoagulation
For most confirmed PE, anticoagulation is the foundation of treatment unless contraindicated. Select the agent using renal/hepatic function, bleeding, procedures, oral absorption, interactions and cancer status. When parenteral treatment is needed, the 2026 guideline generally favors LMWH over UFH in categories C1–E1, including selected patients undergoing endovascular treatment. UFH remains useful in particular circumstances, such as a need for rapid interruption or substantial renal impairment; “postoperative” alone does not establish its superiority.[2]
For suitable adults receiving oral treatment, two common labeled regimens are:[5][6]
| Drug | Initial PE treatment | Thereafter |
|---|---|---|
| Apixaban | 10 mg twice daily for 7 days | 5 mg twice daily |
| Rivaroxaban | 15 mg twice daily for 21 days, with food | 20 mg once daily, with food |
These are treatment regimens, not prophylaxis or extended-phase doses. Check the full label for renal/hepatic restrictions and interactions; do not apply atrial-fibrillation dose-reduction rules automatically to acute VTE. Dabigatran and edoxaban require preceding parenteral treatment and have their own dose-selection rules.[2][5][6]
Cancer-associated PE can be treated with an appropriate DOAC or LMWH. GI/GU bleeding lesions, interactions, absorption and planned procedures matter; a diagnosis of any GI cancer is not an automatic exclusion of every DOAC. High-risk antiphospholipid syndrome, especially triple positivity, favors a vitamin K antagonist. Pregnancy requires a separate pathway.[2][5]
COBRRA: Acute Oral Treatment, 2026
In the 2,760-patient randomized COBRRA trial, clinically relevant bleeding over three months occurred in 44/1,345 apixaban recipients (3.3%) versus 96/1,355 rivaroxaban recipients (7.1%; RR 0.46, 95% CI 0.33–0.65). This endpoint combined major and clinically relevant nonmajor bleeding. The primary abstract supports a bleeding advantage in the studied acute-VTE population; registered criteria excluded active cancer, CrCl below 30 mL/min and weight above 120 kg. It is not a trial confined to fresh surgical patients.[7][8]
Duration and Extended Treatment
Separate the initial 3–6-month treatment phase from the decision to continue. PE following a resolved major reversible factor, such as major surgery, often permits stopping after the initial phase. An unprovoked event or persistent risk factor may justify extended treatment after reassessing bleeding and preferences. Active cancer is persistent, not a strong transient provoking factor. Revisit the balance as cancer, mobility, renal function and bleeding change.[2]
Reduced-dose apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily is an extended-phase option after at least six months of treatment, not a way to underdose a new PE.[5][6]
- API-CAT, 2025: 1,766 patients with active cancer who had already completed at least six months of anticoagulation were randomized to apixaban 2.5 versus 5 mg twice daily for a further year. Recurrent VTE was 2.1% versus 2.8%, meeting the prespecified noninferiority criterion; clinically relevant bleeding was 12.1% versus 15.6%. This supports reduced-dose extended treatment in eligible cancer patients, not initial treatment or every cancer/bleeding circumstance. Recent major surgery within two weeks and several high-risk groups were excluded.[9][10]
- RENOVE, 2025: in 2,768 patients selected for extended anticoagulation, reduced-dose apixaban/rivaroxaban did not meet the noninferiority criterion versus full dose. Estimated five-year recurrent VTE was 2.2% versus 1.8% (HR 1.32, 95% CI 0.67–2.60); clinically relevant bleeding was lower with reduced dosing. Low event rates and less bleeding do not establish equivalent efficacy for every high-recurrence-risk patient.[11]
Reperfusion and Escalation
Activate the local PE response/critical-care team for shock, deterioration, major RV failure or difficult bleeding-versus-treatment decisions. Reperfusion choices include systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy and surgical embolectomy; availability, severity and contraindications determine selection. VA-ECMO may provide support in selected refractory cases at experienced centers.[2][12]
Systemic thrombolysis is not routine for every normotensive PE with RV strain. PEITHO reduced death/hemodynamic decompensation in its intermediate-risk population but increased major extracranial bleeding and stroke. Those data must not be presented as a fixed mortality benefit in postoperative shock. Recent major surgery substantially changes the bleeding balance.[13]
Catheter-directed thrombolysis still administers a thrombolytic. Lower local dosing does not make it a safe workaround for every surgical bleeding contraindication. Mechanical thrombectomy avoids a lytic but introduces vascular access, blood-loss and cardiopulmonary procedural risks. Neither approach is indicated simply because a clot is large.[2][12]
HI-PEITHO: Selected Intermediate-Risk Patients, 2026
The open-label, blinded-adjudication HI-PEITHO trial randomized 544 patients with RV enlargement, elevated troponin and additional clinical severity features to ultrasound-facilitated catheter thrombolysis plus anticoagulation or anticoagulation alone. Seven-day PE-related death, decompensation/collapse or recurrent PE occurred in 11/273 (4.0%) versus 28/271 (10.3%); the difference was driven mainly by decompensation. Major bleeding in the treated population was 11/271 (4.1%) versus 6/271 (2.2%), a nonsignificant difference that does not prove equivalent safety. This trial was published after the new guideline's release.[14]
HI-PEITHO's registered criteria excluded major surgery or trauma within the preceding three weeks. Its result does not establish safety of catheter thrombolysis immediately after pelvic reconstruction. The trial also does not compare ultrasound-facilitated thrombolysis with mechanical thrombectomy or establish a mortality benefit.[14][15]
The Postoperative Patient
There is no automatic rule that mandates a filter before 48 hours, LMWH until day 7, or a DOAC thereafter. Establish the actual bleeding site and hemostasis, drains/catheters, hemoglobin trend, renal function, planned reoperation and gastrointestinal function. Consult the operating and PE teams promptly; prophylaxis is not sufficient treatment while this decision is made.
If therapeutic anticoagulation is feasible, start an appropriate regimen with monitoring and a clear escalation plan. An oral transition requires reliable intake/absorption and a procedural plan, not just a calendar date. Coordinate every therapeutic dose with any neuraxial catheter using the antithrombotic workflow.
IVC filters: consider a retrievable filter when acute PE cannot be anticoagulated, with an explicit follow-up/removal plan. Do not add one routinely to effective anticoagulation. Recurrent PE despite optimized treatment is a selected, weak-guideline option after confirming recurrence, adherence, dose and interactions; it is not an automatic indication. Remove a retrievable filter when protection is no longer needed and anticoagulation is tolerated.[2]
Follow-Up and Persistent Symptoms
Arrange contact or a visit within one week after discharge and reassessment by three months. Review medication access/adherence, bleeding, recurrence symptoms, recovery and treatment duration. Ask about functional limitation and persistent dyspnea at follow-up for at least one year.[2]
Persistent symptoms after at least three months of effective treatment warrant evaluation for post-PE problems, including chronic thromboembolic pulmonary disease with or without pulmonary hypertension. Testing is directed by the clinical picture, often including echocardiography and perfusion imaging, with referral to a specialist center when indicated. Do not diagnose CTEPH from an isolated pressure estimate or repeat CTPA routinely in every asymptomatic survivor.[2]
References
1. Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA. 2022;328:1336–1345. doi:10.1001/jama.2022.16815
2. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of acute pulmonary embolism in adults. Circulation. 2026;153:e977–e1051. doi:10.1161/CIR.0000000000001415
3. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311:1117–1124. doi:10.1001/jama.2014.2135
4. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70:2411–2420. doi:10.1016/j.jacc.2017.09.024
5. ELIQUIS (apixaban). US prescribing information. DailyMed label.
6. XARELTO (rivaroxaban). US prescribing information. DailyMed label.
7. Castellucci LA, et al. Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism. N Engl J Med. 2026. doi:10.1056/NEJMoa2510703
8. COBRRA trial, NCT03266783. Registered eligibility and trial record.
9. Mahé I, Carrier M, Didier R, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med. 2025;392:1363–1373. doi:10.1056/NEJMoa2416112
10. API-CAT trial, NCT03692065. Registered eligibility and trial record.
11. Couturaud F, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405:725–735. doi:10.1016/S0140-6736(24)02842-3
12. Goldberg JB, Giri J, Kobayashi T, et al. Surgical management and mechanical circulatory support in high-risk pulmonary embolisms: AHA scientific statement. Circulation. 2023;147:e628–e647. doi:10.1161/CIR.0000000000001117
13. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–1411. doi:10.1056/NEJMoa1302097
14. Rosenfield K, et al. Ultrasound-facilitated, catheter-directed fibrinolysis for acute pulmonary embolism. N Engl J Med. 2026. doi:10.1056/NEJMoa2516567
15. HI-PEITHO trial, NCT04790370. Registered eligibility and trial record.